Sugi Predict

Sugi Predict / Compounds / SCHEMBL18823908

SCHEMBL18823908

SCHEMBL18823908

CC(C)(C)NC(=O)C1CN1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ ALDH1A1 P00352 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.35
▸ EPHX2 P34913 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ SSTR4 P31391 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ CHRNB2 P17787 1/20 0.33
▸ CHRNA7 P36544 1/20 0.33
▸ CHRNA4 P43681 1/20 0.33
▸ EPHX1 P07099 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ SLC1A3 P43003 1/20 0.32
▸ SLC1A2 P43004 1/20 0.32
▸ SLC1A1 P43005 1/20 0.32
▸ POLB P06746 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652033 0.86 L3MBTL1 (0.50) L3MBTL1ALDH1A1HDAC8EPHX2TSHR
SCHEMBL7558532 0.86 L3MBTL1 (0.50) L3MBTL1ALDH1A1HDAC8EPHX2TSHR
SCHEMBL1900804 0.86 L3MBTL1 (0.50) L3MBTL1ALDH1A1HDAC8EPHX2TSHR
SCHEMBL7273833 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1HDAC8EPHX2CYP1A2
SCHEMBL2731973 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1HDAC8EPHX2CYP1A2
SCHEMBL27392159 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1HDAC8EPHX2SSTR4
SCHEMBL6533367 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1HDAC8EPHX2CYP1A2
SCHEMBL7267347 0.84 L3MBTL1 (0.61) L3MBTL1ALDH1A1HDAC8EPHX2CYP1A2
Hydrochloric Acid SCHEMBL7306318 0.82 L3MBTL1 (0.59) L3MBTL1ALDH1A1HDAC8EPHX2SSTR4
Hydrochloric Acid SCHEMBL8906162 0.82 L3MBTL1 (0.59) L3MBTL1ALDH1A1HDAC8EPHX2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230053449-A1 DC-SIGN ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2023-02-23 — — US disclosed
US-11357864-B2 Antibody drug conjugates for ablating hematopoietic stem cells NOVARTIS AG (CH) 2022-06-14 — — US disclosed
US-20220162308-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF NOVARTIS AG (CH) 2022-05-26 — — US disclosed
US-20210346387-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST NOVARTIS AG (CH) 2021-11-11 — — US disclosed
US-10973826-B2 Antibody conjugates comprising toll-like receptor agonist NOVARTIS AG (CH) 2021-04-13 — — US disclosed
US-10787480-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2020-09-29 — — US disclosed
US-20200164084-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES NOVARTIS AG (CH) 2020-05-28 — — US disclosed
US-20190321483-A1 ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2019-10-24 — — US disclosed
US-10392421-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2019-08-27 — — US disclosed
US-10280139-B2 Cytotoxic peptides and conjugates thereof NOVARTIS AG (CH) 2019-05-07 — — US disclosed
US-20180155281-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2018-06-07 — — US disclosed
US-20170121421-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST NOVARTIS AG (CH) 2017-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787480-B2 Cytotoxic peptides and conjugates thereof CD47, NGLY1, VIP L3MBTL1 2207/4885ALDH1A1 3311/4885HDAC8 3631/4885
US-20170121421-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR2, TLR9 L3MBTL1 1314/4885ALDH1A1 3021/4885HDAC8 1245/4885
US-10392421-B2 Cytotoxic peptides and conjugates thereof CD47, NGLY1, VIP L3MBTL1 2207/4885ALDH1A1 3311/4885HDAC8 3631/4885
US-20230053449-A1 DC-SIGN ANTIBODY DRUG CONJUGATES DCUN1D4, CD14, DCUN1D3 L3MBTL1 2370/4885ALDH1A1 2550/4885HDAC8 1542/4885
US-20210346387-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR2, TLR9 L3MBTL1 1314/4885ALDH1A1 3021/4885HDAC8 1245/4885
US-10973826-B2 Antibody conjugates comprising toll-like receptor agonist TLR3, TLR2, TLR9 L3MBTL1 1314/4885ALDH1A1 3021/4885HDAC8 1245/4885
US-11357864-B2 Antibody drug conjugates for ablating hematopoietic stem cells BCR, ABL1, CD47 L3MBTL1 1097/4885ALDH1A1 167/4885HDAC8 651/4885
US-20180155281-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF CD47, MKI67, NGLY1 L3MBTL1 2207/4885ALDH1A1 3229/4885HDAC8 3272/4885
US-20190321483-A1 ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS BCR, ABL1, CD47 L3MBTL1 1097/4885ALDH1A1 167/4885HDAC8 651/4885
US-20220162308-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF ITGB8, ITGA8, CD4 L3MBTL1 3923/4885ALDH1A1 1567/4885HDAC8 144/4885
US-20200164084-A1 ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES TLR3, TLR2, TLR9 L3MBTL1 851/4885ALDH1A1 2626/4885HDAC8 1123/4885
US-10280139-B2 Cytotoxic peptides and conjugates thereof CD47, MKI67, NGLY1 L3MBTL1 2207/4885ALDH1A1 3229/4885HDAC8 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.